
INOVIO PHARMACEUTICALS INC
INONASDAQTrading Snapshot
- Day Range
- $0.75 โ $0.77
- 52-Week Range
- $0.56 โ $2.98
- Volume
- $2.62B
- Avg Volume
- $2.11B
- Shares Outstanding
- 69.1M
- Next Earnings
- Sep 1, 2026
Fundamentals Snapshot
- Annual Revenue
- $65,343
- Last Q Revenue
- $18,086
- P/E Ratio
- -0.4
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-1.23
- Dividend Yield
- 0.00%
Why Investors Own INO
- โHigh-growth profile โ revenue up +47.1% YoY with expanding US Equity exposure.
- โHealthy economics โ 66% gross margin and 10% free-cash-flow margin.
- โNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About INOVIO PHARMACEUTICALS INC
Inovio Pharmaceuticals, Inc. is a biotechnology firm dedicated to the research, development, and market introduction of DNA-based treatments. Its core mission is to prevent and cure illnesses associated with human papillomavirus (HPV), various types of cancer, and infectious diseases. The company's advanced DNA medicine platform utilizes meticulously engineered SynCon sequences to precisely identify and optimize the genetic blueprint of a target antigen. This innovative approach is supported by its CELLECTRA smart device technology, which efficiently delivers the DNA plasmids. Inovio is actively engaged in and planning clinical trials for its DNA medicines across a wide array of conditions. These include HPV-related precancerous lesions, such as cervical, vulvar, and anal dysplasia; HPV-driven cancers affecting areas like the head and neck, cervix, anus, penis, vulva, and vagina; and other HPV-associated disorders like recurrent respiratory papillomatosis. Beyond HPV, its pipeline addresses glioblastoma multiforme, prostate cancer, and a range of infectious diseases, including HIV, Ebola, Middle East Respiratory Syndrome (MERS), and Lassa fever. The company benefits from a vast network of collaborators and partners, encompassing prominent academic institutions, government agencies, non-profit foundations, and pharmaceutical corporations. Key examples include AstraZeneca, The Bill & Melinda Gates Foundation, the Coalition for Epidemic Preparedness Innovations (CEPI), the Defense Advanced Research Projects Agency (DARPA), the National Institutes of Health, Regeneron Pharmaceuticals, and the University of Pennsylvania. Significant partnerships also involve an agreement with Richter-Helm BioLogics GmbH & Co. KG to further develop the investigational COVID-19 DNA vaccine INO-4800, alongside a strategic alliance with the International Vaccine Institute and Seoul National University Hospital. Established in 1979, Inovio Pharmaceuticals is headquartered in Plymouth Meeting, Pennsylvania.
Otter Score Breakdown
โAnalyst Ratings
โLatest News & Updates
Piper Sandler Reiterates Overweight on Inovio Pharmaceuticals, Lowers Price Target to $4
Piper Sandler analyst Edward Tenthoff reiterates Inovio Pharmaceuticals (NASDAQ:INO) with a Overweight and lowers the price target from $6 to $4.

Here are the top movers in Thursday's session.
Wondering how the US markets performed one hour before the close of the markets on Thursday? Discover the movers and shakers of today's session in our comprehensive analysis.

Let's uncover which stocks are experiencing notable gaps during today's session.
The session on Thursday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.

12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Nuwellis (NASDAQ:NUWE) stock moved upwards by 123.7% to $4.23 during Thursday's regular session. GlucoTrack (NASDAQ:GCTK) shares moved upwards by 79.85% to $0.51. The company's market cap stands at

Stay updated with the stocks that are on the move in today's pre-market session.
Before the opening bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.

Nasdaq Surges Over 600 Points; Microsoft Shares Jump After Upbeat Q4 Results
US stocks rise with Nasdaq up 600 points, Dow up 0.69% and S&P 500 up 1.29%. Tech shares up 5%, communication services down 3.3%. Microsoft jumps 15% after strong earnings.